The Patent Is a Distraction. Vaxart's Real Story Is a $344.8 Million Government Bet

Vaxart, Inc. announced today that the European Patent Office granted it European Patent 3791859 for its room-temperature-stable, needle-free oral norovirus vaccine pill, protecting the candidate in 13 European countries through at least 2036. It is the kind of release designed to make a $0.32 stock sound like progress. The useful question is whether it is.

Patents are a moat, not a product. A granted patent keeps rivals from copying your delivery technology; it does not produce a dollar of revenue, does not fund a clinical trial, and says nothing about whether the pill works at scale. For a company whose entire financial life is a chain of cash and data dates, that distinction is the whole game.

Start with where the money actually comes from. Vaxart is a clinical-stage biotech that trades around $0.32 per share after being delisted from Nasdaq in September 2025 for failing the $1 minimum-bid requirement, and now trades over the counter on the OTCQX. There are roughly 243 million shares outstanding, which values the entire company at about $78 million — barely more than the $64 million of cash and investments it reported on June 30. Subtract the cash and the market is pricing the whole pipeline — norovirus, COVID, flu, the platform itself — at about $14 million of value.

The counterweight to that discount is the U.S. government. In June 2024, BARDA, the federal agency that funds pandemic preparedness, awarded Vaxart a Project NextGen contract originally valued at up to $453 million to run a large Phase 2b trial of its next-generation oral COVID-19 pill against an approved mRNA vaccine. It is a cost-reimbursement deal, so the company recognizes revenue as it spends on the trial. By the end of September 2025, Vaxart had already drawn $125.9 million in cash payments under the award. This is how the company can report $27.2 million of second-quarter revenue while selling no product at all.

The award has been trimmed since. In August 2025, BARDA ordered a partial termination that cut enrolled participants by roughly half, and authorized funding was reset to about $344.8 million — including a June 2026 modification that released an additional $29 million to finish the study and run deeper analysis. What remains is a trial of a 400-person sentinel cohort plus a main cohort of about 5,085 participants, dosed against the KP.2 viral strain, with topline results due in the first half of 2027. Twelve-month safety data from the sentinel cohort, reported in July 2026, were clean: no vaccine-related serious adverse events in either the pill or the mRNA arm.

There is also a partner. In November 2025, Vaxart licensed the COVID pill to Dynavax for up to $700 million in cumulative proceeds plus royalties, including $25 million upfront, a $5 million equity investment, and $50 million due after Phase 2b results. Vaxart still pays for the trial; Dynavax is waiting with money at the registration door. That is the financial spine: a government-funded study to a 2027 decision, and a partner whose contingent fees arrive only if the data are good. Today's patent touches none of it.

The norovirus corner is where the patent's timing gets interesting. No norovirus vaccine is approved anywhere, for a virus that causes an estimated 19 to 21 million cases and $10.6 billion in annual costs in the U.S. each year. The deep-pocketed injectable challengers have both stumbled. HilleVax, the Takeda spinout, dropped its candidate for infants after a mid-stage miss in July 2024. Moderna's mRNA-1403 Phase 3 trial did not meet the statistical criteria for early success, disclosed with its second-quarter 2026 results. Vaxart's oral pill, by contrast, met five of its six primary endpoints in a 2023 human challenge study — a statistically significant 29% reduction in infections and an 85% cut in viral shedding, though the reduction in acute gastroenteritis missed statistical significance. The company disclosed as far back as 2021 that its earlier European coverage of norovirus and RSV intellectual property faced an opposition challenge, so this new 2036-dated grant is genuine incremental armor in a field that just emptied.

Now the discipline. A cheap stock is not a reason to own it, and a fallen stock's discount is not automatically a mispricing. Part of the market's wariness here is earned: this is a penny-stock OTC tape, dilution has been relentless, and the cash runway runs only into the second quarter of 2027 — roughly the same quarter the company is waiting on its H1 2027 COVID readout. The norovirus program is not funded to a pivotal trial, and the post-pandemic market for a COVID pill is unproven even with Dynavax attached.

The honest reading is a watchlist item with a named break condition, not a headline buy. Everything re-rates — or doesn't — on one funded readout: about 5,000 patients' worth of Phase 2b data in the first half of 2027, followed by whatever financing consequences follow, including the $50 million Dynavax fee if the study merits it. The patent stretches the norovirus asset's shelf life while that question is answered. It does not change the odds of the answer.

At $0.32, the market prices the last standing advanced oral norovirus program at roughly $14 million on top of cash — against $344.8 million in authorized government funding and a disease that costs the U.S. $10.6 billion a year. That divergence is the story worth following. The patent is a footnote inside it.